4 years ago

Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study

Tania Gavilán Iglesias, Pablo Martínez-Martín, Lidia Vela, Fuencisla Gutiérrez, Luis González Gutiérrez, Leonidas Stefanis, Vincenzo Lupo, Paula Pires, Miguel Coelho, Julio Ramos Lizana, Miguel Tomás Vila, Belén Pérez Dueñas, Joaquim Ferreira, Carlos Hernández Lahoz, Laura Martí Sánchez, Nardo Nardocci, María Josep Martí, Ana Castro Caldas, Montserrat Pujol, Cristina Garrido, Giovanna Zorzi, Itziar Gastón, Paulo Rego, Fradique Moreira, Loreto Martorell, Jean Pierre Lin, Kylee Tustin, Gustavo Lorenzo Sanz, Marina Magalhães, Alejandra Darling, Carmen Espinós, Leonor Correia Guedes, María Stamelou, Cristina Costa, Cristina Tello, Marcos Madruga, Sergio Aguilera-Albesa, Carmen Rodríguez-Blazquez, Teresa Temudo, Daniel Cuadras Pallejà, Juan Darío Ortigoza Escobar, Pedro J. García, Roser Pons
Background Pantothenate kinase-associated neurodegeneration is a progressive neurological disorder occurring in both childhood and adulthood. The objective of this study was to design and pilot-test a disease-specific clinical rating scale for the assessment of patients with pantothenate kinase-associated neurodegeneration. Methods In this international cross-sectional study, patients were examined at the referral centers following a standardized protocol. The motor examination was filmed, allowing 3 independent specialists in movement disorders to analyze 28 patients for interrater reliability assessment. The scale included 34 items (maximal score, 135) encompassing 6 subscales for cognition, behavior, disability, parkinsonism, dystonia, and other neurological signs. Results Forty-seven genetically confirmed patients (30 ± 17 years; range, 6-77 years) were examined with the scale (mean score, 62 ± 21; range, 20-106). Dystonia with prominent cranial involvement and atypical parkinsonian features were present in all patients. Other common signs were cognitive impairment, psychiatric features, and slow and hypometric saccades. Dystonia, parkinsonism, and other neurological features had a moderate to strong correlation with disability. The scale showed good internal consistency for the total scale (Cronbach's α = 0.87). On interrater analysis, weighted kappa values (0.30-0.93) showed substantial or excellent agreement in 85% of the items. The scale also discriminated a subgroup of homozygous c.1583C>T patients with lower scores, supporting construct validity for the scale. Conclusions The proposed scale seems to be a reliable and valid instrument for the assessment of pediatric and adult patients with pantothenate kinase-associated neurodegeneration. Additional validation studies with a larger sample size will be required to confirm the present results and to complete the scale validation testing. © 2017 International Parkinson and Movement Disorder Society

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/mds.27129

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.